Across the recent three months, 4 analysts have shared their insights on IDEXX Laboratories (NASDAQ:IDXX), expressing a variety of opinions spanning from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $491.5, a high estimate of $550.00, and a low estimate of $435.00. Observing a downward trend, the current average is 10.58% lower than the prior average price target of $549.67.

Exploring Analyst Ratings: An In-Depth Overview

The analysis of recent analyst actions sheds light on the perception of IDEXX Laboratories by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of IDEXX Laboratories's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on IDEXX Laboratories analyst ratings.

Delving into IDEXX Laboratories's Background

IDEXX Laboratories: Delving into Financials

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: IDEXX Laboratories's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.56%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: IDEXX Laboratories's net margin excels beyond industry benchmarks, reaching 23.87%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): IDEXX Laboratories's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.56% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): IDEXX Laboratories's ROA excels beyond industry benchmarks, reaching 6.88%. This signifies efficient management of assets and strong financial health.

Debt Management: IDEXX Laboratories's debt-to-equity ratio surpasses industry norms, standing at 0.62. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Significance of Analyst Ratings Explained

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.